Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression

Rebecca E Graff*[,1,2], Allison Meisner[3], Thomas U Ahearn[1], Michelangelo Fiorentino[1,4,5], Massimo Loda[4,6], Edward L Giovannucci[1,7,8], Lorelei A Mucci[1,7] and Andreas Pettersson[1,9] for the Transdisciplinary Prostate Cancer Partnership (ToPCaP)

[1]Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA; [2]Department of Epidemiology & Biostatistics, University of California San Francisco, 1450 3rd Street, San Francisco, CA 94158, USA; [3]Department of Biostatistics, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA; [4]Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; [5]Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Via Pietro Albertoni, 15, 40138 Bologna, Italy; [6]Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; [7]Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA; [8]Department of Nutrition, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA and [9]Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden

Background: Experimental studies have shown androgen receptor stimulation to facilitate formation of the TMPRSS2:ERG gene fusion in prostate cell lines. No study has tested whether higher pre-diagnostic circulating sex hormone levels in men increase risk of developing TMPRSS2:ERG-positive prostate cancer specifically.

Methods: We conducted a nested case–control study of 200 prostate cancer cases and 1057 controls from the Physicians' Health Study and Health Professionals Follow-up Study. We examined associations between pre-diagnostic circulating levels of total testosterone, free testosterone, DHT, androstanediol glucuronide, estradiol, and SHBG and risk of prostate cancer by TMPRSS2:ERG status. TMPRSS2:ERG was estimated by ERG immunohistochemistry. We used multivariable unconditional polytomous logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for risk of ERG-positive ($n = 94$) and, separately, ERG-negative ($n = 106$) disease.

Results: Free testosterone was significantly associated with the risk of ERG-positive prostate cancer (OR: 1.37, 95% CI: 1.05–1.77), but not ERG-negative prostate cancer (OR: 1.09, 95% CI: 0.86–1.38) ($P_{diff} = 0.17$). None of the remaining hormones evaluated showed clear differential associations with ERG-positive vs ERG-negative disease.

Conclusions: These findings provide some suggestive evidence that higher pre-diagnostic free testosterone levels are associated with an increased risk of developing TMPRSS2:ERG-positive prostate cancer.

Intraprostatic androgens play a critical role in normal prostate development and prostate carcinogenesis. Numerous studies have investigated associations between pre-diagnostic circulating sex hormone levels and prostate cancer risk, with mixed but overall null results (Roddam et al, 2008). Previous studies, however, have not considered the molecular heterogeneity of prostate cancer. In

particular, there is biological plausibility that sex hormones could differentially affect the development of prostate cancer with or without the somatic *TMPRSS2:ERG* gene fusion (Tomlins *et al*, 2005). Roughly half of prostate tumours harbour this fusion between the androgen-regulated gene *TMPRSS2* and the oncogene *ERG* (Setlur *et al*, 2008; Tomlins *et al*, 2009; Rubin *et al*, 2011). Experimental work has shown that exposure of both malignant and non-malignant prostate epithelial cells to androgens can facilitate *TMPRSS2:ERG* formation (Lin *et al*, 2009; Mani *et al*, 2009; Bastus *et al*, 2010; Haffner *et al*, 2010). It is thus plausible that higher pre-diagnostic circulating sex hormone levels, especially of androgens, could increase the risk of developing *TMPRSS2:ERG*-positive prostate cancer. To address this question, we conducted a nested case–control study of 200 prostate cancer cases and 1057 controls assessing the associations between pre-diagnostic circulating levels of total testosterone, free testosterone, dihydrotestosterone (DHT), androstanediol glucuronide (a metabolite of DHT), estradiol, and sex hormone-binding globulin (SHBG) and risk of prostate cancer by ERG protein expression status (a marker of *TMPRSS2:ERG* fusion status).

MATERIALS AND METHODS

Study population. This study included the cases with known ERG protein expression status and all controls from two previously conducted nested case–control studies of pre-diagnostic circulating sex hormone levels and risk of prostate cancer (Gann *et al*, 1996; Platz *et al*, 2005). The first case–control study was nested within the prospective Physicians' Health Study (PHS), a randomised, double-blind, placebo-controlled trial of aspirin and beta carotene among 22 071 US male physicians aged 40 to 84 at baseline in 1982 (Gann *et al*, 1996). The second case–control study was nested within the ongoing prospective Health Professionals Follow-up Study (HPFS), a cohort study of risk factors for disease among 51 529 male health professionals aged 50 to 75 years at baseline in 1986 (Platz *et al*, 2005). In both cohorts, all men were free of diagnosed cancer, other than non-melanoma skin cancer, at baseline. Participants in each cohort responded to a baseline questionnaire and follow-up questionnaires are mailed regularly (annually in the PHS and biennially in the HPFS) to update information on potential risk factors and to identify newly diagnosed illnesses. Prostate cancer diagnoses are self-reported and then confirmed through medical record review.

In the PHS, blood was collected from 68% of participants ($n = 14\,916$) prior to randomisation. From among those who provided blood, every incident prostate cancer case occurring by March 1992 was matched to two living controls who had not reported a diagnosis of prostate cancer at the time of the case's diagnosis (Gann *et al*, 1996). Controls were also matched on smoking status (never, former, current) and age within 1 year, except for two case patients who were over 80 at diagnosis for whom age was matched within 2 years. In total, 222 eligible cases and 390 eligible controls had plasma samples sufficient for analysis. In the HPFS, blood was collected from 18 018 participants free from prostate cancer between 1993 and 1995. From among those who provided blood, every incident prostate cancer case occurring by August 2000 was matched to one living control who had a prostate specific antigen (PSA) test after blood draw and had not reported a diagnosis of prostate cancer at the time of the case's diagnosis (Platz *et al*, 2005). Additional matching criteria were year of birth (within 1 year), PSA test before blood draw (yes, no), timing of blood draw (midnight–before 0900 hours, 0900 hours–before noon, noon–1600 hours and after 1600 hours–before midnight), season of draw (winter, spring, summer, fall) and year of draw (exact). In total, 691 eligible case–control pairs had sufficient plasma samples for analysis.

The cases for this study initially included the 203 cases (PHS: 37/HPFS: 166) for whom tumour ERG expression status was available. We then excluded two T1a cases from the HPFS because such tumours are generally indolent and most susceptible to detection bias due to differential rates of surgery for benign prostatic hyperplasia. We additionally excluded 1 case and 17 controls who had a diagnosis of cancer other than non-melanoma skin cancer before the date of blood draw and 7 controls with a blood draw date after the date of their matched case's diagnosis. The remaining 200 cases and 1057 controls comprised the analytical population for this study.

This study was approved by the Human Subjects Committee at the Harvard T.H. Chan School of Public Health and by Partners Health Care. Written informed consent was obtained from each subject.

Measurement of sex hormone levels. The measurement of sex hormone levels has been previously described in detail (Gann *et al*, 1996; Platz *et al*, 2005) and is outlined in Supplementary Table S1. In the PHS, plasma was assayed for total testosterone, DHT, estradiol, androstanediol glucuronide and SHBG in a single analytical run in December 1994. In the HPFS, measurement of sex hormone levels was completed in three waves: index date of diagnosis from blood draw to January 1996, February 1996 to January 1998, January 1998 to August 2000. Plasma was assayed for total testosterone, free testosterone, DHT (first two waves only), androstanediol glucuronide, estradiol and SHBG. For samples from both the PHS and the HPFS, cases and their matched controls were analysed together and laboratory personnel were unable to distinguish case, control and quality control samples.

Tumour tissue collection and assessment of *TMPRSS2:ERG* status. In both the PHS and HPFS, prostate tumour tissue has been collected from participants having undergone radical prostatectomy (RP) or transurethral resection of the prostate (TURP). Tissue microarrays have been constructed by taking three or more 0.6-mm cores of tissue from the primary tumour nodule or nodule with the highest Gleason grade.

We estimated presence or absence of *TMPRSS2:ERG* by immunohistochemical assessment of ERG protein expression as previously described (Pettersson *et al*, 2012). In short, ERG antisera (1 : 100, Clone ID: EPR3864, Epitomics, Inc., Burlingame, CA, USA) were applied to 0.5-μm TMA sections and visualisation of ERG was accomplished using the DAB substrate kit (Vector Laboratories Inc., Burlingame, CA, USA). A case was scored *TMPRSS2:ERG* positive if at least one TMA core had positive ERG staining within prostate cancer epithelial cells. Of cases positive for ERG on at least one core, 85% stained positive for ERG in all cores. Previous studies have shown ERG protein expression to be strongly correlated with *TMPRSS2:ERG* fusion status as assessed by other methods (Park *et al*, 2010; Chaux *et al*, 2011; van Leenders *et al*, 2011).

Statistical analysis. Because sex hormones were assayed in several batches, we adjusted for the effect of batch using methods previously described (Rosner *et al*, 2008). In brief, these methods involve regressing log-transformed hormone levels on batch. For all statistical analyses, batch-adjusted log-transformed hormone levels were modelled as continuous variables to maximise power, and we assessed 1 s.d. increases.

We first used unconditional binary logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between sex hormones and risk of prostate cancer overall. We then used unconditional polytomous logistic regression, an extension of binary logistic regression that allows for nominal outcome variables, to study associations with three outcomes: ERG-positive prostate cancer, ERG-negative prostate cancer and controls. To maximise power, we combined the two

cohorts and adjusted for all matching factors used in either cohort. We also ran models additionally adjusted for body mass index (BMI) at blood draw and cohort. Missing data for model covariates (<10% for all covariates) were assigned to the mode value for categorical variables and the median value for continuous variables.

We conducted each of the analyses described for each of the hormones individually. Then, because estradiol and testosterone both bind to SHBG, we ran additional models for estradiol and, separately, testosterone that adjusted for SHBG, and a model including all three factors. To further explore findings from a previous study (Black et al, 2014), we also ran models of a ratio of estradiol to testosterone, both unadjusted and adjusted for SHBG. In sensitivity analyses, we excluded participants with statistically extreme hormone levels according to the generalised Extreme Studentized Deviate many-outlier detection approach (Rosner, 1983).

We also conducted analyses in which we restricted to Caucasian men since both sex hormone levels and the prevalence of TMPRSS2:ERG differ by ethnicity. Finally, we ran sensitivity analyses excluding 10 cases with ERG assayed in TURP specimens or tissue from an unknown source, excluding cases diagnosed within 1 year of blood draw, by cohort separately, and using conditional logistic regression of matched sets.

Analyses were conducted using SAS version 9.2 (SAS Institute, Inc. Cary, NC). All tests were two-sided and P-values < 0.05 were considered to be statistically significant.

RESULTS

Characteristics of the 1057 controls, 106 ERG-negative cases and 94 ERG-positive cases are presented in Table 1. The mean time

Table 1. Characteristics of prostate cancer cases by ERG status and matched controls in the Physicians' Health Study and Health Professionals Follow-up Study

	Controls	ERG − cases	ERG + cases	P_{diff}[a]
Number	1057	106	94	
Caucasian, n (%)	1003 (97.5%)	102 (98.1%)	89 (98.9%)	1.00
Characteristics at blood draw				
Mean age, years (s.d.)	63.8 (7.6)	62.4 (6.6)	59.9 (7.3)	0.01
Mean BMI, $kg\,m^{-2}$ (s.d.)	25.4 (3.2)	25.5 (3.0)	25.0 (2.8)	0.22
Current smoker, n (%)	65 (6.2%)	7 (6.6%)	8 (8.5%)	0.61
Ever PSA Test, n (%)	459 (45.0%)	54 (52.9%)	58 (61.7%)	0.22
Time of blood draw, n (%)				
Midnight–before 0900 hours	307 (32.2%)	28 (29.8%)	32 (38.1%)	
0900 hours–before 1200 hours	490 (51.4%)	52 (55.3%)	35 (41.7%)	
1200 hours–before 1600 hours	128 (13.4%)	12 (12.8%)	13 (15.5%)	
1600 hours–before midnight	29 (3.0%)	2 (2.1%)	4 (4.8%)	0.28
Season of blood draw, n (%)				
Winter	167 (15.8%)	19 (17.9%)	16 (17.0%)	
Spring	206 (19.5%)	23 (21.7%)	18 (19.2%)	
Summer	235 (22.2%)	27 (25.5%)	29 (30.9%)	
Autumn	449 (42.5%)	37 (34.9%)	31 (33.0%)	0.86
Mean batch-adjusted hormone levels (s.d.)				
Total testosterone, $ng\,ml^{-1}$	4.8 (1.7)	5.0 (1.9)	5.1 (1.7)	0.90
Free testosterone, $pg\,ml^{-1}$	15.4 (4.4)	15.9 (4.3)	16.8 (4.4)	0.17
Dihydrotestosterone, $ng\,ml^{-1}$	0.4 (0.2)	0.4 (0.3)	0.4 (0.2)	0.73
Androstanediol glucuronide, $ng\,ml^{-1}$	6.4 (5.0)	7.5 (6.1)	6.9 (3.9)	0.37
Estradiol, $pg\,ml^{-1}$	32.4 (9.6)	32.4 (10.6)	32.9 (9.4)	0.73
Sex hormone-binding globulin, $nmol\,l^{-1}$	45.1 (21.3)	46.8 (23.0)	44.3 (16.8)	0.38
Characteristics at diagnosis				
Mean time from blood draw to diagnosis, years (s.d.)	—	3.7 (2.3)	3.7 (2.3)	0.88
Mean age, years (s.d.)	—	66.4 (6.3)	64.1 (6.9)	0.01
Mean PSA, $ng\,ml^{-1}$ (s.d.)	—	9.8 (8.8)	7.9 (4.8)	0.11
Pathological stage, n (%)[b]				
T2 N0/NX	—	78 (83.0%)	59 (63.4%)	
T3 N0/NX	—	16 (17.0%)	30 (32.3%)	
T4/N1/M1	—	0 (0.0%)	4 (4.3%)	0.001
Gleason grade, n (%)				
2–6	—	15 (16.1%)	17 (19.8%)	
3 + 4	—	35 (37.6%)	34 (39.5%)	
4 + 3	—	25 (26.9%)	17 (19.8%)	
8–10	—	18 (19.4%)	18 (20.9%)	0.61
Year of diagnosis, n (%)				
1982–1990	—	17 (16.0%)	9 (9.6%)	
1991–1995	—	31 (29.3%)	31 (33.0%)	
1996–2000	—	58 (54.7%)	54 (57.5%)	0.36

Abbreviations: BMI = body mass index; PSA = prostate specific antigen.
[a]P-value for difference between ERG − and ERG + ; based on Fisher's exact test for race and time of blood draw, t-tests for age at blood draw and diagnosis, BMI at blood draw, hormone levels, time from blood draw to diagnosis, PSA at diagnosis; χ^2-tests for smoking status at blood draw, ever PSA test at blood draw, season of blood draw; Cochran–Armitage trend test for pathological stage (exact), Gleason grade, year of diagnosis.
[b]Restricted to 187 radical prostatectomy specimens with stage data available (out of 190 radical prostatectomy specimens total).
NOTE: numbers may not add up as expected for characteristics with missing data; percentages may not add up as expected due to rounding.

Table 2. Odds ratios and 95% confidence intervals for 1 s.d. increase in log-transformed and batch-adjusted hormone levels and risk of ERG-negative and, separately, ERG-positive prostate cancer

Hormone	#Controls/ERG − / ERG +	s.d.[a]	All case/control OR (95% CI)[b]	ERG − /control OR (95% CI)[c]	ERG + /control OR (95% CI)[c]	P_{diff}[d]
Total testosterone	1054/106/94	0.39	1.15 (0.98, 1.36)	1.12 (0.90, 1.38)	1.20 (0.95, 1.52)	0.63
Free testosterone	659/82/79	0.29	1.21 (1.00, 1.46)	1.09 (0.86, 1.38)	1.37 (1.05, 1.77)	0.17
Dihydrotestosterone	827/82/69	0.60	1.04 (0.87, 1.24)	1.03 (0.81, 1.30)	1.04 (0.80, 1.35)	0.93
Androstanediol glucuronide	1051/106/94	0.58	1.16 (1.00, 1.36)	1.22 (0.99, 1.49)	1.11 (0.90, 1.37)	0.51
Estradiol	1054/106/94	0.31	1.00 (0.85, 1.17)	0.95 (0.78, 1.16)	1.07 (0.84, 1.35)	0.44
SHBG	1054/106/94	0.49	1.13 (0.95, 1.34)	1.14 (0.91, 1.42)	1.12 (0.88, 1.44)	0.94
Total testosterone adjusted for SHBG	1054/106/94	0.39	1.12 (0.91, 1.37)	1.06 (0.82, 1.37)	1.20 (0.90, 1.59)	0.52
Total testosterone adjusted for SHBG and estradiol	1054/106/94	0.39	1.13 (0.92, 1.40)	1.09 (0.83, 1.42)	1.19 (0.88, 1.60)	0.65
Estradiol adjusted for SHBG	1054/106/94	0.31	0.99 (0.85, 1.17)	0.95 (0.78, 1.16)	1.07 (0.84, 1.35)	0.43
Estradiol adjusted for SHBG and total testosterone	1054/106/94	0.31	0.97 (0.82, 1.14)	0.93 (0.76, 1.15)	1.03 (0.80, 1.31)	0.53
Estradiol/total testosterone ratio	1054/106/94	0.44	0.88 (0.75, 1.03)	0.88 (0.72, 1.08)	0.89 (0.71, 1.12)	0.90
Estradiol/total testosterone ratio adjusted for SHBG	1054/106/94	0.44	0.91 (0.76, 1.10)	0.91 (0.72, 1.15)	0.92 (0.71, 1.20)	0.92

Abbreviations: BMI = body mass index; CI = confidence interval; OR = odds ratio; SHBG = sex hormone-binding globulin.
[a] s.d. of log-transformed, batch-adjusted hormone.
[b] From binary logistic regression models adjusted for age at blood draw (continuous), smoking status at blood draw (yes, no), ever PSA test prior to blood draw (yes, no), time of blood draw (midnight–0900 hours, 0900 hours–before 1200 hours, 1200 hours–before 1600 hours, 1600 hours–before midnight), season of blood draw (winter, spring, summer, fall) and time between blood draw and index date (continuous).
[c] From polytomous logistic regression models adjusted for the variables listed above.
[d] Based on the Wald χ^2-statistic from comparing the exposure parameters for each outcome vs control from the polytomous logistic regression model.

between blood draw and case diagnosis was 3.7 years. Cases in total were more likely than controls to have received a PSA test prior to blood draw. Among cases only, as previously reported (Pettersson *et al*, 2012), those who were ERG positive were younger at diagnosis and had higher stage tumours relative to those who were ERG negative.

Table 2 presents associations of sex hormones and risk of prostate cancer overall and by ERG status for 1 s.d. increases in the biomarkers. Increasing levels of total testosterone ($OR_{per s.d.}$: 1.15, 95% CI: 0.98–1.36) and free testosterone ($OR_{per s.d.}$: 1.21, 95% CI: 1.00–1.46, measured in the HPFS only) were associated with an elevated risk of prostate cancer overall. While DHT was not associated with risk of prostate cancer overall ($OR_{per s.d.}$: 1.04, 95% CI: 0.87–1.24), its primary metabolite androstanediol glucuronide was positively associated ($OR_{per s.d.}$: 1.16, 95% CI: 1.00–1.36). Neither estradiol ($OR_{per s.d.}$: 1.00, 95% CI: 0.85–1.17) nor SHBG ($OR_{per s.d.}$: 1.13, 95% CI: 0.95–1.34) were significantly associated with overall prostate cancer risk, but the latter did demonstrate a non-significant positive relationship.

In a polytomous model assessing the risk of ERG-negative and ERG-positive cancer separately, free testosterone (measured in the HPFS only) was significantly associated with the risk of ERG-positive prostate cancer (OR: 1.37, 95% CI: 1.05–1.77), but not ERG-negative prostate cancer (OR: 1.09, 95% CI: 0.86–1.38) ($P_{diff} = 0.17$). None of the remaining hormones evaluated suggested differential associations with ERG-positive *vs* ERG-negative disease (all $P_{diff} > 0.40$).

Adjustment for estradiol and/or SHBG did not materially alter the results for associations between total testosterone and prostate cancer. Likewise, adjustment for total testosterone and/or SHBG did not appreciably change the results for estradiol. The ratio of estradiol to testosterone was not associated with prostate cancer risk overall or by ERG tumour status.

No more than three outliers were detected for any hormone in any one assay batch. Results from sensitivity analyses excluding outliers were comparable to those from the main analyses. Similarly, additional adjustment for BMI, restriction to Caucasian men, exclusion of cases with ERG assayed in TURP specimens or

tissue from an unknown source and exclusion of cases diagnosed within 1 year of blood draw did not materially alter the results (data not shown). The use of conditional logistic regression of matched sets only attenuated the results for free testosterone; the OR was 1.24 (95% CI: 0.84–1.83) for ERG-positive disease and 1.15 (95% CI: 0.82–1.61) for ERG-negative disease. On running analyses by cohort power was substantially reduced, particularly for the PHS (22 ERG-negative cases and 15 ERG-positive cases). Still, total testosterone was significantly associated with overall prostate cancer risk in the HPFS (OR: 1.25, 95% CI: 1.04–1.51), but not in the PHS (OR: 0.91, 95% CI: 0.62–1.33). No other results were significant in either cohort, except those for free testosterone (measured in the HPFS only).

DISCUSSION

In this nested case–control study of pre-diagnostic circulating sex hormones levels and risk of prostate cancer by ERG status, free testosterone was positively associated with risk of ERG-positive disease but unassociated with ERG-negative disease. None of the remaining hormones evaluated showed clear differential associations with ERG-positive *vs* ERG-negative prostate cancer. These findings provide some suggestive evidence that higher pre-diagnostic androgen levels are associated with an increased risk of developing *TMPRSS2:ERG*-positive disease specifically.

Experimental studies have shown that androgen receptor stimulation induces spatial proximity between *TMPRSS2* and *ERG* in both malignant and non-malignant prostate epithelial cells (Lin *et al*, 2009; Mani *et al*, 2009; Bastus *et al*, 2010). In addition, they have demonstrated that long-term (5 months) exposure to DHT alone (Bastus *et al*, 2010), or short-term (≤24 h) exposure to DHT plus gamma radiation (Lin *et al*, 2009; Mani *et al*, 2009), causes the formation of *TMPRSS2:ERG*. Other studies have investigated prostate cancer characterised by *TMPRSS2:ERG* status with respect to a polymorphic CAG repeat sequence in the first exon of *androgen receptor* gene that is associated with reduced

transcriptional activity (Bastus *et al*, 2010; Figg *et al*, 2014; Mao *et al*, 2014; Yoo *et al*, 2014). Some (Bastus *et al*, 2010; Yoo *et al*, 2014), but not all (Figg *et al*, 2014; Mao *et al*, 2014), suggested that shorter repeat length may be specifically associated with the development of *TMPRSS2:ERG*-positive disease. The sum of these studies lends plausibility to the hypotheses that higher circulating pre-diagnostic sex hormones, and especially androgens, could be associated with the development of ERG-positive disease, and that the formation of *TMPRSS2:ERG* could be an initiating event or selected for during prostate tumour development. We found some evidence in support of these hypotheses, in that free testosterone trended towards stronger associations with ERG-positive disease. That the association with ERG-positive disease was present for free rather than total testosterone is noteworthy; free testosterone (i.e., testosterone that is unbound from SHBG or albumin) is a better measure of bioavailable testosterone for uptake into cells (Rosner *et al*, 2007). Still, all of the associations in our clinical data in humans were meager relative to evidence of associations between androgens and the induction of *TMPRSS2:ERG* in cell lines (Lin *et al*, 2009; Mani *et al*, 2009; Bastus *et al*, 2010; Haffner *et al*, 2010). Perhaps most conspicuous, we did not find any association between DHT and ERG-positive prostate cancer. It could be that higher levels of circulating androgens alone are insufficient to induce the DNA double-strand breaks that result in *TMPRSS2:ERG* formation; paracrine signalling or other factors that activate nuclear androgen receptor could be required (Pienta and Bradley, 2006; Taplin, 2007; Harris *et al*, 2009). The hypothesis that higher androgen levels increase the risk of *TMPRSS2:ERG*-positive prostate cancer is further challenged by evidence that CAG repeats are shorter (Buchanan *et al*, 2004) and circulating androgen levels are higher (Richard *et al*, 2014) in black than white men, but the prevalence of *TMPRSS2:ERG*-positive tumours is substantially higher in white ($\sim$50%) than black ($\sim$30%) men (Magi-Galluzzi *et al*, 2011; Rosen *et al*, 2012).

Many epidemiological studies have evaluated associations between circulating androgens and prostate cancer risk, with largely null results (Gann *et al*, 1996; Platz *et al*, 2005; Roddam *et al*, 2008). In the original case–control study from the PHS, investigators found that increasing total testosterone adjusted for SHBG was associated with prostate cancer risk ($P_{trend} = 0.004$) (Gann *et al*, 1996). The original study from the HPFS did not return similarly significant results (Platz *et al*, 2005). Having consolidated the data from the two studies, we found, as expected, suggestive evidence that androgens may increase total prostate cancer risk, but with the exception of free testosterone, results were non-significant.

A limitation of this study is the relatively small number of cases assayed for ERG status, and that ERG protein expression was assessed rather than the *TMPRSS2:ERG* fusion itself. Cases assayed for ERG status, which were largely treated with RP, may not be representative of all men diagnosed with prostate cancer. In addition, our limited sample sizes precluded analyses of non-linear relationships and hindered meaningful interpretation of the results from the PHS (pre-PSA era) and HPFS (PSA era) separately. We were also unable to evaluate associations in non-Caucasian individuals. Still, our study was borne from a well-annotated prospective cohort with tumour tissue, plasma, and clinical data. Our analyses also adjusted for potentially important confounding variables, including age. Last, we were able to measure plasma hormone levels prior to diagnosis, thereby sidestepping any issues of reverse causation.

In summary, our study provides some suggestive evidence of associations between circulating free testosterone and risk of ERG-positive prostate cancer. Given the plausibility and experimental data in favour of the biological hypothesis, more studies should pursue this research question in the hopes of improving strategies for the primary prevention of disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM, Lu YJ (2010) Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. *Cancer Res* **70**(23): 9544–9548.

Black A, Pinsky PF, Grubb 3rd RL, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB (2014) Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer. *Cancer Epidemiol Biomarkers Prev* **23**(11): 2374–2382.

Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD (2004) Structural and functional consequences of glutamine tract variation in the androgen receptor. *Hum Mol Genet* **13**(16): 1677–1692.

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. *Am J Surg Pathol* **35**(7): 1014–1020.

Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS (2014) Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. *Urology* **84**(1): 127–131.

Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst* **88**(16): 1118–1126.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S (2010) Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. *Nat Genet* **42**(8): 668–675.

Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* **6**(2): 76–85.

Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. *Cell* **139**(6): 1069–1083.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. *Prostate* **71**(5): 489–497.

Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM (2009) Induced chromosomal proximity and gene fusions in prostate cancer. *Science* **326**(5957): 1230.

Mao X, Li J, Xu X, Boyd LK, He W, Stankiewicz E, Kudahetti SC, Cao G, Berney D, Ren G, Gou X, Zhang H, Lu YJ (2014) Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer. *Am J Cancer Res* **4**(6): 886–896.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia* **12**(7): 590–598.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA (2012) The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* **21**(9): 1497–1509.

Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. *Clin Cancer Res* **12**(6): 1665–1671.

Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. *Cancer Epidemiol Biomarkers Prev* **14**(5): 1262–1269.

Richard A, Rohrmann S, Zhang L, Eichholzer M, Basaria S, Selvin E, Dobs AS, Kanarek N, Menke A, Nelson WG, Platz EA (2014) Racial variation in sex steroid hormone concentration in black and white men: a meta-analysis. *Andrology* **2**(3): 428–435.

Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. *J Natl Cancer Inst* **100**(3): 170–183.

Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Bohm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S (2012) Differences in frequency of ERG oncoprotein expression between index tumours of Caucasian and African American patients with prostate cancer. *Urology* **80**(4): 749–753.

Rosner B (1983) Percentage points for a generalised ESD many-outlier procedure. *Technometrics* **25**(2): 165–172.

Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. *Am J Epidemiol* **167**(6): 653–666.

Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (2007) Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab* **92**(2): 405–413.

Rubin MA, Maher CA, Chinnaiyan AM (2011) Common gene rearrangements in prostate cancer. *J Clin Oncol* **29**(27): 3659–3668.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA (2008) Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer. *J Natl Cancer Inst* **100**(11): 815–825.

Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. *Nat Clin Pract Oncol* **4**(4): 236–244.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *Eur Urol* **56**(2): 275–286.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* **310**(5748): 644–648.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J (2011) Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. *Mod Pathol* **24**(8): 1128–1138.

Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, Mucci LA (2014) Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. *Cancer Epidemiol Biomarkers Prev* **23**(10): 2027–2031.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)